Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biocruces Bizkaia (8)

2023

  1. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

    EJNMMI Physics, Vol. 10, Núm. 1

  2. The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis

    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.., Vol. 67, Núm. 1, pp. 83-92

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

2020

  1. Feasibility and limitations of quantitative SPECT for 223Ra

    Physics in Medicine and Biology, Vol. 65, Núm. 8

2019

  1. Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively

    Physica Medica, Vol. 65, pp. 143-149

  2. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT

    European Journal of Cancer Care, Vol. 28, Núm. 5

2018

  1. Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with 223Ra

    Physics in Medicine and Biology, Vol. 63, Núm. 14